PIK3CG

(redirected from PI3K-gamma)

PIK3CG

A gene on chromosome 7q22.3 that encodes the gamma catalytic subunit of phosphoinositide-3-kinase (PI3K), which phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol-3,4,5-triphosphate (PIP3). This gamma catalytic subunit forms a heterodimer with PIK3R5 or PIK3R6 regulatory subunits; its interaction with ADRBK1 through the PIK helical domain is required for targeting to agonist-occupied receptor. It is thought to interact with PDE3B, TPM2 and EPHA8, and to regulate integrin-mediated cell adhesion to substrates.
Mentioned in ?
References in periodicals archive ?
FDA seeking full approval for its lead product candidate duvelisib, a first-in-class oral dual inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma, for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and accelerated approval for the treatment of relapsed or refractory follicular lymphoma.
The company is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met the primary endpoints in both a Phase 2 study in double-refractory iNHL and a Phase 3 clinical trial in patients with relapsed/refractory CLL/SLL.
Under the amended agreement, Infinity will no longer have an obligation to pay Takeda future royalties on worldwide net sales of selective inhibitors of PI3K-gamma, including IPI-549.
Infinity is developing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma.
IPI-549 is an oral immuno-oncology development candidate that is designed to selectively inhibit phosphoinositide-3-kinase (PI3K)-gamma and is the only investigational PI3K-gamma inhibitor in clinical development.
DYNAMO is a Phase 2 clinical study evaluating duvelisib, the company's investigational oral monotherapy, dual inhibitor of phosphoinositide-3-kinase -delta and PI3K-gamma, in patients with indolent non-Hodgkin lymphoma whose disease is refractory to both rituximab and chemotherapy or radioimmunotherapy.
AbbVie, a global biopharmaceutical company, will present data on its investigational medicine venetoclax, a B-cell lymphoma -2 (BCL-2) inhibitor, and duvelisib, an investigational phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma inhibitor, at the 21st European Hematology Association (EHA) Annual Congress, June 9-12, in Copenhagen, Denmark.
The contract has been signed to develop and commercialise duvelisib, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, to treat patients with cancer.
Verastem is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in iNHL and is currently being evaluated in a Phase 3 clinical trial in patients with CLL.